Researchers develop antibodies that degrade and inhibit difficult-to-target GPCRs
Researchers reported a bispecific antibody platform called GPCR–TfR1 targeting chimeras (GTACs) in a study published online by Nature on 30 September 2026. The antibodies bind both a G-protein-coupled receptor (GPCR) and transferrin receptor 1 (TfR1),…
